 |
|
 |
 |

Home > Company Index > Drugs > Diagnostic Substances > Ostex International, Inc.
 |
Ostex International, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Self-administered US test aims to measure bone loss Aug 18 2001 08:07 AM PDT
Ostex wins FDA approval for broader use of bone test Aug 15 2001 08:48 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
Battling brittle bones is Ostex International's bag. The company develops therapies and diagnostics for skeletal and connective-tissue diseases. Ostex's first product, Osteomark, is a urine test that measures the rate of a person's bone loss; the test can lead to the prevention and treatment of osteoporosis. The company also makes an Osteomark blood test to detect osteoarthritis at an early stage by measuring collagen levels in joint cartilage. Ostex's partners include Johnson & Johnson (which distributes Osteomark in the US and elsewhere), Mochida Pharmaceutical (its Japanese distributor), and Metrika (which, with Ostex, has developed a point-of-care Osteomark test).
COMPETITION |
 |
Gemini Genomics plc (GMNI)
NPS Pharmaceuticals, Inc. (NPSP)
Quidel Corporation (QDEL)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 5.60
1-Yr. Sales Growth: 19.1%
Employees: 45
Revenue per employee: $124,444.44
KEY PEOPLE |
 |
Thomas A. Bologna
CEO
CONTACT INFO |
 |
2203 Airport Way South, Ste. 400
Seattle, WA 98134
US
Phone: 206-292-8082
Fax: 206-292-8625
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |